Eclipse Regenesis Awarded National Institutes of Health (NIH) Grant

Eclipse Regenesis, Inc., developer of the first restorative therapy to address pediatric and adult Short Bowel Syndrome, has been awarded a National Institutes of Health Small Business Innovation Research (NIH SBIR) Fast Track grant of $1.7 million. These funds will be used to further develop the Eclipse XL1 System™, which is designed to harness the body’s own regenerative capabilities via a process called distraction enterogenesis to produce new fully functional intestinal tissue as a potential treatment for SBS.

Short Bowel Syndrome (SBS) is a devastating condition where the small intestine is too short to absorb sufficient nutrients to sustain a patient. Current treatments include intravenous nutrition, drug therapy and intestinal surgery or transplantation, which have low success rates and high five-year costs of up to $1.6 million per patient. The award will support further development of the Eclipse XL1 System to take the device from the laboratory to the clinic.

“We are honored that the National Institutes of Health (NIH) has funded our SBIR proposal as there is a huge unmet clinical need in a rare, but very debilitating, condition that we are trying to address,” said Eclipse Regenesis CEO Andre Bessette. “These patients, and in many cases babies, suffer every day and their quality of life can be severely comprised. We hear regularly from parents and patients who are eager to learn more about the progress of our technology and are desperate for new solutions. The funds from the NIH will enable us to accelerate the development of our technology to make intestinal tissue regeneration an option for these patients, both pediatric and adult.”

The Eclipse XL1’s mechanism of action has been studied in conjunction with several top academic institutions, whose work has been published in more than 20 peer reviewed publications.

The NIH Fast Track grant combines submission and review of Phase I (pre-clinical) and Phase II (clinical) grants as one application. Because both phases undergo review at the same time, the mechanism enables uninterrupted funding through clinical study of new therapies. This funding for Eclipse Regenesis, Inc. is supported by The National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number R44DK127658.

The company also recently received a National Science Foundation Small Business Innovation Research grant to support development of a minimally-invasive version of the Eclipse XL1 System. Additionally, Eclipse Regenesis is one of the newest companies to join the Fogarty Innovation Company Accelerator Program, a renowned six-month program for promising early-stage medical technology companies.